Illumina Hit With Antitrust Suit Over Alleged Patent Fraud
Law360 (January 11, 2021, 10:04 PM EST) -- Illumina stifled competition with fraudulently obtained patents and "baseless" infringement litigation, a rival company alleged Monday in a suit filed in California federal court, accusing the gene-sequencing behemoth of maintaining U.S. market dominance by defrauding the patent office and echoing the Federal Trade Commission's proclamation that Illumina is a "monopolist."
Complete Genomics, a subsidiary of the Chinese genome-sequencing company BGI Group, claims that Illumina Inc. and Illumina Cambridge Ltd. violated the Sherman Antitrust Act and California's unfair competition laws by asserting at least three patents against it in federal court "in an unlawful, anticompetitive manner."
"Through this fraud and baseless patent litigation,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!